Allen Loyd V
International Journal of Pharmaceutical Compounding.
Int J Pharm Compd. 2020 Jan-Feb;24(1):44-50.
Intravenous admixture compounding requires a knowledge of stability, compatibility, and incompatibility issues related to the complete composition and formulation of the admixture. Referring to tables, charts, etc. is valuable but not always sufficient to determine whether or not a specific intravenous admixture will be stable and compatible. In evaluating an intravenous admixture, one is not just concerned with the active ingredients but with all the excipients. Excipients used in the formulations of commercially available products may vary between manufacturers, and these variations can influence drug compatibility and stability. Clinical pharmaceutics involves the study and application or pharmaceutics to real-life clinical compounding situations to aid in the evaluation of each intravenous admixture. This series continues with compatibility considerations in intravenous admixture compounding and will cover most aspects of the issues involved, to include in-syringe admixtures and small-volume and large-volume admixtures.
静脉药物混合配制需要了解与混合制剂的完整成分和配方相关的稳定性、相容性和不相容性问题。参考表格、图表等是有价值的，但要确定特定的静脉混合制剂是否稳定且相容，这些并不总是足够的。在评估静脉混合制剂时，人们关注的不仅仅是活性成分，还包括所有辅料。市售产品配方中使用的辅料可能因制造商而异，这些差异会影响药物的相容性和稳定性。临床药剂学涉及药剂学在实际临床配制情况中的研究和应用，以帮助评估每种静脉混合制剂。本系列将继续探讨静脉药物混合配制中的相容性问题，并将涵盖所涉及问题的大多数方面，包括注射器内混合制剂以及小容量和大容量混合制剂。
